Share on LinkedInShare on LinkedIn

ARTICLE · 17 JUNE 2022

Intellectual Property Due Diligence In Psychedelics

The market for psychedelic substances is projected to grow rapidly, potentially outpacing the legal US cannabis market. But evaluating the promise, and the risk, of a psychedelics...

United StatesIntellectual Property

The market for psychedelic substances is projected to grow rapidly, potentially outpacing the legal US cannabis market. But evaluating the promise, and the risk, of a psychedelics IP portfolio is still mired in unknowns. What should investors be looking for in this nascent industry?

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. Whether derived from the plant or developed in the lab, the bare-naked molecule is unlikely to be eligible for patent protection. For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from